Please login to the form below

Not currently logged in
Email:
Password:

Circassia

This page shows the latest Circassia news and features for those working in and with pharma, biotech and healthcare.

Circassia exits allergy R&D after placebo effect strikes again

Circassia exits allergy R&D after placebo effect strikes again

Circassia exits allergy R&D after placebo effect strikes again. Abandons phase IIb trial of house dust mite allergy candidate. ... That deal was valued at up to $230m, with Circassia giving AZ $50m in shares in return for the rights to the two drugs.

Latest news

  • Circassia slumps as cat allergy vaccine fails late-stage trial Circassia slumps as cat allergy vaccine fails late-stage trial

    Circassia slumps as cat allergy vaccine fails late-stage trial. Has suspended several trials after an “ unprecedented” placebo effect derailed leading drug candidate. ... UK biotech Circassia Pharma has suffered a major blow as its lead cat allergy

  • Allergy specialist Circassia buys asthma firms Allergy specialist Circassia buys asthma firms

    Allergy specialist Circassia buys asthma firms. British-based company acquires Sweden’ s Aerocrine and privately held Prosonix. ... Circassia will pay £139m ($219m) for Aerocrine and up to £100m for Prosonix.

  • The M&A trend in pharma The M&A trend in pharma

    Pet allergy (and biotech) company Circassia's £200m IPO has so far represented the largest of these deals in the life sciences sector this year.

  • Lilly invests in UK life sciences via biotech fund Lilly invests in UK life sciences via biotech fund

    This year has already seen allergy specialist Circassia raise £200m in an initial public offering (IPO) after years in which a small biotech companies had to partner with a larger company

  • TxCell plans listing as EU biotech wakes up to IPOs

    TxCell plans listing as EU biotech wakes up to IPOs. Move follows UK allergy therapy developer Circassia's listing. ... TxCell's move comes shortly after UK allergy therapy developer Circassia raised £200m ($333m) via an IPO on the London Stock Exchange

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    One of Imperial College’s research ventures has culminated in the development of Circassia Pharmaceuticals, a spin-out biotech whose co-founders were at the time testing a prototype vaccine technology ... This year, Circassia established a commercial

  • Deal Watch March 2017 Deal Watch March 2017

    If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.

  • Pharma deals in May 2015 Pharma deals in May 2015

    155. Prosonix/Circassia. Corporate acquisition. Portfolio of generic respiratory products includingfluticasone. 152.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics